Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The landscape of airway disease management has been fundamentally altered by the arrival of biologic therapies targeting type 2 (T2) inflammation. Inhaled corticosteroids, beta-agonists, and anticholinergics once defined the ceiling of what was pharmacologically possible for patients with 

 and COPD — but that ceiling has since shattered. Beginning with omalizumab and continuing through mepolizumab, benralizumab, and dupilumab, a wave of precision agents has reshaped how pulmonologists think about inflammatory airway disease, transforming severe asthma from a condition of symptom management to one where clinical remission is an achievable and increasingly discussed treatment goal.

The pace of that transformation has accelerated in recent years. Dupilumab's 2023 FDA approval for COPD with type 2 inflammation — the first biologic ever cleared for that indication — marked a paradigm shift in how the field approaches a disease long considered beyond the reach of precision medicine.¹ Mepolizumab followed with its own COPD approval, supported by the MATINEE trial, which demonstrated significant exacerbation reduction in patients with blood eosinophil counts of 300 cells/µL or higher.² The GOLD 2025 guidelines have now formally incorporated eosinophil counts and T2 biomarkers into the COPD escalation algorithm,³ and emerging CT-based data on mucus plug scoring are beginning to explain why dupilumab produces such striking improvements in lung function in certain patients.⁴ Meanwhile, tezepelumab — which demonstrated exacerbation reduction regardless of baseline T2 biomarker status in the NAVIGATOR trial⁵ — has challenged the eosinophil-centric framework that guided biologic prescribing for the better part of a decade. Most recently, depemokimab, an ultra-long-acting IL-5 inhibitor dosed every six months, received FDA approval for severe eosinophilic asthma,⁶ introducing a new approach to adherence in difficult-to-treat populations.

It is against this backdrop that HCPLive convened an expert forum on the Evolving Landscape of Targeted Therapy in Asthma and COPD, led by Geoffrey Chupp, MD, Professor of Medicine and director of the Asthma and Airway Disease program at Yale University. The panel included clinicians from academic medical centers and private practice across the Northeast who reviewed the clinical trial evidence base, debated biomarker thresholds, and shared candid accounts of what biologic prescribing actually looks like in busy outpatient clinics — far removed from the controlled environments of phase 3 trials.

The panel reached broad consensus on several core principles while revealing meaningful variation in individual practice. In asthma, blood eosinophils — with a preferred cutoff of ≥300 cells/μL — remain the cornerstone biomarker for biologic initiation, though FeNO and atopy testing add important nuance. Most panelists place patients on a biologic after 2 or more OCS courses per year, though Chupp and others advocated for lower thresholds in highly symptomatic patients even without documented exacerbations. Dupilumab was frequently cited as a first-line choice for patients with nasal polyps or predominant IL-13 signaling, while tezepelumab has emerged as the clear go-to agent for patients with low or absent T2 markers. Depemokimab's 6-month dosing interval generated enthusiasm for vulnerable and non-adherent populations, with panelists generally favoring a short-acting IL-5 first to confirm efficacy before transitioning. The long-term extension data for all approved biologics showed consistent durability, and newer trial data on mucus plug scores — from the VESTIGE trial with dupilumab and the CASCADE trial with tezepelumab — added a compelling radiographic dimension to understanding how these drugs drive lung function improvements.

“It's helpful to have a marker to trend in these patients to sort of see did the biologic really improve things or not. I think I have a pretty similar threshold to others and what others have mentioned in terms of actually starting a biologic. I mean, typically one course of prednisone won't do it for me. But if they're one course and they're really uncontrolled, multiple courses, like two courses, I'm definitely starting,” Sandy Zaeh, MD, MS, Pulmonary & Critical Care Medicine physician at Yale School of Medicine, said during the forum.

In COPD, the panel reflected a field still finding its footing with biologic therapy. Dupilumab was the dominant choice in practice, backed by the stronger exacerbation and lung function data from BOREAS and NOTUS, while mepolizumab's COPD uptake remained limited, hampered by comparatively modest effect sizes in MATINEE and insurance access barriers that panelists in New Jersey and other markets described vividly. Several clinicians noted that COPD patients are meaningfully harder to engage with biologic therapy than asthma patients — older, more injection-averse, and often skeptical that additional treatment can improve their quality of life. Yet those who have initiated therapy described consistently positive patient experiences, with even modest functional gains translating into meaningful improvements in daily life. The group identified long-term lung function trajectory data, clearer patient selection algorithms, and improved payer alignment as the most pressing unmet needs — and one panelist made the case bluntly: if a single avoided COPD hospitalization can offset years of biologic costs, the math on coverage restrictions is hard to defend.

Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. 

. 2023;389(3):205-214. doi:10.1056/NEJMoa2303951

Eger K, Hashimoto S, Braunstahl GJ, et al. Mepolizumab for eosinophilic COPD with exacerbations (MATINEE). 

. 2024;391(1):21-31. doi:10.1056/NEJMoa2401300

Global Initiative for Chronic Obstructive Lung Disease. 

Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report

Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. 

. 2018;128(3):997-1009. doi:10.1172/JCI95693

Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. 

. 2021;384(19):1800-1809. doi:10.1056/NEJMoa2034975

Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the efficacy and safety of depemokimab in patients with severe asthma with an eosinophilic phenotype (SWIFT-1 and SWIFT-2). 

. 2024;404(10471):2373-2385. doi:10.1016/S0140-6736(24)02063-4

Articles

Type 2–targeted biologics have expanded airway disease management beyond inhaled therapies, reframing severe asthma around achievable clinical remission and introducing precision medicine into selected COPD. Recent milestones include dupilumab and mepolizumab approvals for eosinophilic COPD and guideline integration of eosinophils/T2 biomarkers into escalation pathways, alongside emerging CT mucus-plug phenotyping. Expert consensus favors eosinophils ≥300/µL plus FeNO/atopy to refine asthma selection, with practice variation around OCS thresholds, agent choice, and real-world adherence challenges.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Eosinophils, Exacerbations, and Endpoints: Biologic Therapy Selection in COPD and Asthma

Experts discuss the clinical significance of the updated international CSU guidelines, which for the first time incorporate 3 step-up therapy options.

Overview of the New International CSU Guidelines and Expanded Treatment 

The updated international guidelines for chronic spontaneous urticaria (CSU) represent the most substantive revision to the treatment algorithm since the 2022 iteration, most notably with the formal incorporation of dupilumab and remibrutinib as recommended step-up therapies alongside omalizumab for patients inadequately controlled on high-dose antihistamines. This expansion is clinically significant given that approximately 50% of CSU patients fail antihistamine-based regimens regardless of dose escalation. Dupilumab, an interleukin-4 receptor alpha (IL-4Rα) antagonist with established use across multiple type 2 inflammatory conditions, brings a known safety profile and approval down to age 12, while remibrutinib offers a novel oral Bruton tyrosine kinase (BTK) inhibitory mechanism with demonstrated rapid onset of action in adult patients.

The practical implications differ by specialty. In dermatology, where high patient volume and workflow considerations have historically limited omalizumab utilization — including the agent's black-box warning, which does not apply to the urticaria indication, and the burden of clinic wait times — having an oral agent and a biologic with broader prescribing familiarity may substantially expand the pool of patients receiving guideline-concordant step-up therapy. In allergy/immunology, where omalizumab has been used more routinely, these new agents enrich the shared decision-making framework by allowing clinicians to tailor therapy to individual patient preferences, comorbidities, and logistical factors such as medication preparation and administration burden.

In this video discussion on CSU guideline updates, Jason Hawkes, MD, dermatologist at Oregon Medical Research Center and an author on the new guidelines, and Nicole Chase, MD, an allergist/immunologist in private practice and associate professor of medicine at the University of Minnesota, examine what these changes mean for clinicians across both specialties. Both experts emphasize that expanding the available options is not simply a matter of convenience — it directly addresses longstanding gaps in care for a population that has had limited recourse when antihistamine strategies have failed, and that the availability of a fast-acting oral agent alongside 2 established biologics meaningfully changes the conversation clinicians can have with patients about what relief is realistically achievable.

Videos

Nicole Negbenebor, MD, is a clinical assistant professor of dermatology and the director of the Skin of Color Clinic for the University of Iowa, as well as a Skin of Color Society (SOCS) member.

Discussing Work as the Director of a Skin of Color Clinic in Dermatology

Skin of Color Savvy: The Art and Science of Treating Patients of Color

 in partnership with the Skin of Color Society (SOCS), Nicole Negbenebor, MD, clinical assistant professor of dermatology and director of the Skin of Color Clinic at the University of Iowa, highlights key clinical and cultural considerations when caring for patients with skin of color.

Negbenebor discusses how dermatologic conditions in diverse patient populations often require a broader clinical perspective integrating cultural awareness with evidence-based care. While many dermatologic diseases present across all skin types, she notes differences in pigmentary response, hair-care practices, and product use can influence both disease presentation and treatment outcomes. As a result, dermatologists must remain attentive to patient-specific factors potentially shaping clinical decision-making.

A central theme of the discussion is the importance of listening to patients and creating an environment where individuals feel comfortable discussing their concerns. Negbenebor notes patients with skin of color may sometimes feel their symptoms or experiences have been overlooked in healthcare settings. Building trust through open communication, particularly around culturally relevant practices such as hair care routines or skincare products, can improve diagnostic accuracy and strengthen therapeutic relationships.

Negbenebor also emphasizes the value of education and mentorship in expanding dermatologists’ ability to care for diverse populations. Through her work at the Skin of Color Clinic at the University of Iowa, she helps train residents to recognize conditions that may be more prevalent or present differently in patients with darker skin types, including pigmentary disorders, scarring alopecias, and inflammatory dermatoses potentially leading to postinflammatory hyperpigmentation.

The segment further underscores the importance of continued research and scholarly engagement in advancing dermatologic care. Negbenebor describes writing and academic work as providing opportunities to highlight patient experiences, address gaps in clinical knowledge, and advocate for improved access to therapies.

Taken together, this portion of the conversation reflects Negbenebor’s broader message throughout the episode: delivering effective dermatologic care requires not only clinical expertise, but also cultural awareness, mentorship, and a commitment to expanding the evidence base for patients with skin of color.

Editor’s note: This summary was developed with the help of AI tools.

In this segment of the latest Skin of Color Savvy podcast, Nicole Negbenebor, MD, highlights her experiences as director of a Skin of Color Clinic.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Experts discuss the goal of complete symptom control in CSU and the practical limitations of achieving complete control of disease.

Treatment Goals, Disease Control Targets, and the Role of Patient-Reported Outcome Measures 

The Urticaria Activity Score over 7 days (UAS7) is the primary validated instrument for measuring CSU disease activity in clinical trials and forms the evidentiary foundation for interpreting treatment efficacy across all 3 agents now recommended in international guidelines. A score of 0 — the formal definition of complete response — requires 7 consecutive days free of both wheals and itch, making it a stringent and difficult-to-achieve endpoint. Even the most effective agents in the current therapeutic landscape fall short of producing a UAS7 of 0 in the majority of treated patients, a limitation the guidelines acknowledge while continuing to endorse complete control as the therapeutic aspiration. Patients who do not reach a UAS7 of 0 can still experience transformative improvement; some achieve scores in the range of 3 to 6 and report that their quality of life has been fundamentally restored, which argues for initiating therapy rather than withholding it in pursuit of a theoretically ideal outcome.

The Urticaria Control Test (UCT) offers a more pragmatic instrument for routine clinical practice, particularly in high-volume dermatology settings where prospective daily symptom tracking is impractical. Although neither tool is universally adopted across specialties, both serve an important documentation function in the current payer environment and should be familiar to prescribing clinicians. Payer requirements for prior authorization of biologic and targeted therapies in CSU are evolving, and maintaining dual assessment — UAS7 and UCT — as part of the intake process may be prudent until coverage criteria are more clearly standardized. A practical concern also exists regarding data quality: many patients complete the UAS7 from memory at clinic visits rather than prospectively, which may diminish the reliability of recorded scores.

In this video segment, Nicole Chase, MD, and Jason Hawkes, MD, converge on a pragmatic middle ground: formal scoring aside, what matters clinically is establishing a baseline sense of disease burden and tracking directional change over time. The expansion of the treatment armamentarium brings renewed relevance to the challenge of incomplete response. With 3 mechanistically distinct step-up agents now available, clinicians can more credibly reassure patients that falling short of complete control on 1 agent does not represent a therapeutic dead end — a reframing that carries particular value in a condition where psychological stress is itself a recognized disease trigger. Communicating realistic but optimistic expectations at the outset supports adherence and reduces the risk that patients disengage from care before meaningful benefit is achieved.

Matthew Krantz, MD, from Vanderbilt University Medical Center

Sayantani Sindher, MD, is a clinical associate professor at the Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine.

Jose Clemente, PhD, associate professor of Genetics and Genomics and Immunology at the Icahn School of Medicine at Mount Sinai

HCPLive Five: AAAAI 2026

2026 American Academy of Allergy, Asthma & Immunology (AAAAI)

 annual meeting in Philadelphia from February 27 – March 2, investigators presented new data spanning drug hypersensitivity, food 

 treatment, microbiome science, and biologic therapies for chronic inflammatory disease.

In this installment of HCPLive Five, the editorial team highlights 5 key expert interviews conducted on site, featuring insights from leading clinicians and investigators on emerging data. Topics include pharmacogenomic risk for lamotrigine-induced DRESS, adjunct biologic strategies for multi-allergen oral immunotherapy (OIT), microbiome modulation in infants born via cesarean delivery, and long-acting biologic therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) and hereditary angioedema (HAE).

HLA-A*32:01 Linked to Lamotrigine DRESS Risk, With Matthew Krantz, MD

New research highlights a strong genetic association between the antiseizure medication lamotrigine and drug reaction with eosinophilia and systemic symptoms (Drug Reaction with Eosinophilia and Systemic Symptoms) among carriers of the HLA-A*32:01 allele. In an interview, Matthew Krantz, MD, of Vanderbilt University Medical Center, discussed prospective case-control findings conducted with Mass General Brigham showing 12-fold increased odds of lamotrigine-induced DRESS among HLA-A*32:01 carriers.

The multi-institutional analysis included 30 confirmed DRESS cases and 300 lamotrigine-tolerant controls from the BioVU biobank. Findings show the potential role of HLA genotyping in clarifying causality when multiple medications are involved and may inform future pharmacogenomic strategies to identify patients at elevated risk for severe lamotrigine hypersensitivity.

Dupilumab Reduces GI Symptoms During Multi-Allergen OIT, With Sayantani Sindher, MD

Findings from the COMBINE trial suggest the biologic dupilumab may improve tolerability and desensitization during omalizumab-facilitated multi-allergen OIT. In an interview, Sayantani Sindher, MD, from Stanford University, discussed results from the randomized study of 108 patients with multiple food allergies undergoing OIT. Although adding dupilumab did not significantly improve sustained unresponsiveness, it increased tolerance to higher allergen doses and reduced gastrointestinal adverse events.

Participants receiving dupilumab tolerated larger allergen exposures and experienced fewer GI symptoms per dose. Findings suggest dupilumab may serve as a targeted adjunct therapy to improve safety and patient experience during multi-allergen OIT.

Vaginal Seeding Partially Modifies Infant Microbiome in ACTIVATE, With Jose Clemente, PhD

Results from the ACTIVATE trial suggest vaginal microbial transfer may partially modify the infant gut microbiome in cesarean-delivered infants and influence early allergy risk. In an interview, Jose Clemente, PhD, from Icahn School of Medicine at Mount Sina, discussed findings showing that vaginal seeding increased colonization with beneficial microbes such as 

 shortly after birth and temporarily shifted microbiome profiles toward those seen in vaginally delivered infants. Although global microbiome differences diminished by 12 months, infants with successful microbial transfer showed lower levels of microbes associated with food sensitization.

Twice-Yearly Depemokimab Reduces Rescue Use in Recurrent CRSwNP, With Josesph Han, MD

A pooled post hoc analysis of ANCHOR-1 and ANCHOR-2 suggests the anti–IL-5 biologic depemokimab may improve disease control in patients with CRSwNP and prior surgery. In an interview, Joseph K. Han, MD, from Old Dominion University, discussed findings showing twice-yearly depemokimab improved nasal obstruction, sense of smell, and health-related quality of life compared with placebo in patients with type 2 inflammation. Depemokimab significantly reduced the need for rescue interventions such as systemic corticosteroids or additional surgery.

Navenibart at 3- and 6-Month Dosing Reduces HAE Attacks, With Adil Adatia, MD

Interim phase 2 ALPHA-SOLAR data suggest the investigational monoclonal antibody navenibart may provide durable prophylaxis for HAE types 1 and 2. In an interview, Adil Adatia, MD, from University of Alberta, reported that both 3-month and 6-month subcutaneous dosing schedules produced substantial reductions in HAE attacks, with median reductions exceeding 95%. The long-acting plasma kallikrein–targeting antibody demonstrated a favorable safety profile, with mostly mild treatment-emergent adverse events and few injection-site reactions.

Investigators also noted improvements in patient quality of life as attack frequency declined. Findings support continued evaluation of navenibart in the ongoing phase 3 ALPHA-ORBIT trial.

This HCPLive Five captures 5 interviews conducted on-site at AAAAI 2026.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

HCPLive Five at AAAAI 2026

Lala discusses the ethical, medical, and practical concerns surrounding xenotransplantation of pig hearts – and how they should be addressed in clinical research.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

ISHLT Provides Updates in Xenografting in Patients with Cardiac Diseases, With Anu Lala, MD

This segment of Bhatia's interview highlights imsidolimab's reported durability of response for those with generalized pustular psoriasis (GPP).

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

Division of Nephrology in the Department of Medicine at Columbia University Irving Medical Center and the Columbia University Renal Epidemiology (CURE) Group in New York

Yu, MD, Adler, MD, share their perspectives from a cohort study on in-sequence, and out of sequence paired kidneys transplants. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Is Expedited Kidney Donation More Effective Than In-Sequence?

Vice Chief of Education, Fellowship Program Director

Division of Gastroenterology and Hepatology at UNC Health Care

Long discusses AFFIRM data showing strong clinical and endoscopic outcomes with SC risankizumab (Skyrizi) induction in Crohn’s disease.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH

Wood discussed factors that go into shared decision making for multi-food allergy.

Omalizumab or Oral Immunotherapy for Food Allergy, With Robert Wood, MD

Daniel DiGiacomo, MD, a clinical immunologist at K. Hovnanian Children's Hospital at Hackensack Meridian Jersey Shore University Medical Center. 

At AAAAI 2026, DiGiacomo discussed how artificial intelligence, genetic testing, and biomarkers could improve diagnosis and precision care.


AI, Genetic Testing May Advance Precision Care in Immunology, With Daniel DiGiacomo, MD

Caleb Alexander, MD, MS, is a professor of epidemiology and medicine at Johns Hopkins University School of Medicine and co-founder and principal of Stage Analytics.

Alexander discusses his recent study comparing 61 trials of 4 main GLP-1 RAs, highlighting their increased efficacy for weight loss in female patients.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

GLP-1 RA Effects are Largely Homogeneous but Stronger in Women than Men, With Caleb Alexander, MD, MS

In this episode, experts discuss solitary confinement, aging in prison, and gaps in care for incarcerated populations.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Medical Ethics Unpacked

Medical Ethics Unpacked is a regular multimedia series hosted by Dominic Sisti, PhD, and Steve Levine, MD, spotlighting a spectrum of topics within the field of medical ethics. Throughout the year, hosts will sit down for an in-depth discussion on a specific ethical dilemma within modern healthcare, with some episodes also featuring a special guest. 

Check back throughout the year for discussions on a variety of topics, including data privacy in health apps, euthanasia and medical assistance in dying, reproductive rights and technologies, and more!

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Medical Ethics Unpacked: Ethical Challenges of Carceral Healthcare

Explore emerging IBD treatments—TL1A blockers, microRNA, stem cells—and new small-bowel imaging, plus team-based care improving access.

UChicago Advances IBD Trials With Focus on Microbiome and Access

Senior Allergy Dietitian at the Royal Children’s Hospital, Clinician-Scientist Fellow at MCRI & Honorary Senior Research Fellow at Melbourne University,

McWilliam discussed findings from the TreEat study at AAAAI 2026.

Latest News

Eosinophils, Exacerbations, and Endpoints: Biologic Therapy Selection in COPD and Asthma

Overview of the New International CSU Guidelines and Expanded Treatment

Discussing Work as the Director of a Skin of Color Clinic in Dermatology

Treatment Goals, Disease Control Targets, and the Role of Patient-Reported Outcome Measures

HCPLive Five at AAAAI 2026